Harvard Bioscience (HBIO) Finished Goods (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Finished Goods data on file, last reported at $5.5 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $5.5 million, up 7.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 7.37% YoY), and the FY2025 annual result was $5.4 million, up 2.85% from the prior year.
• Finished Goods rose to $5.5 million in Q1 2026 per HBIO's latest filing, from $5.4 million in the prior quarter.
• Over five years, Finished Goods peaked at $6.8 million in Q1 2022 and troughed at $4.8 million in Q3 2024.
• A 5-year average of $5.6 million and a median of $5.5 million in 2024 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2022 and 2023: Finished Goods surged 32.93% in 2022, then slipped 24.33% in 2023.
• A 5-year view of Finished Goods shows it stood at $5.2 million in 2022, then decreased by 1.97% to $5.1 million in 2023, then increased by 1.99% to $5.2 million in 2024, then climbed by 2.85% to $5.4 million in 2025, then rose by 2.51% to $5.5 million in 2026.
• Business Quant data shows HBIO's Finished Goods at $5.5 million in Q1 2026, $5.4 million in Q4 2025, and $5.9 million in Q3 2025.